https://her2-2026.pp3.medonline.nl/her2-positief-mammacarcinoom-wetenschappelijke-update/ 2021-08-26T15:36:33+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2022/01/MEDtalks_2.1.png https://her2-2026.pp3.medonline.nl/ema-goedkeuring-enhertu/ 2023-12-20T11:54:50+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2022/01/HER2.png https://her2-2026.pp3.medonline.nl/hormoongevoelig-mammacarcinoom-wetenschappelijke-update/ 2024-01-03T13:38:02+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2022/01/MEDtalks_1.png https://her2-2026.pp3.medonline.nl/diagnostiek-en-betekenis-van-her2-low-mammacarcinoom/ 2024-01-03T13:39:37+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2021/08/OV-scaled-1.jpg https://her2-2026.pp3.medonline.nl/voor-borstkankerpatient-met-uitzaaiingen-bestaat-geen-eenduidig-zorgpad/ 2024-01-03T13:40:53+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2022/12/Voor-borstkankerpatient-met-uitzaaiingen-bestaat-geen-eenduidig-zorgpad.png https://her2-2026.pp3.medonline.nl/samen-beslissen-aandacht-voor-de-mens-achter-de-patient/ 2024-01-03T13:41:33+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2022/12/Samen-beslissen.png https://her2-2026.pp3.medonline.nl/triple-negatief-mammacarcinoom-wetenschappelijke-update/ 2024-01-03T13:42:01+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2022/01/MEDtalks_3.png https://her2-2026.pp3.medonline.nl/video-uitleg-geneesmiddelen-induceerde-ild/ 2024-01-04T15:29:39+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2023/12/Video-uitleg-geneesmiddelen-induceerde-ILD-.png https://her2-2026.pp3.medonline.nl/t-dxd-in-de-behandeling-van-2l-her2-mbc-met-en-zonder-hersenmetastasen/ 2024-11-18T10:39:13+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2024/11/Danny-Houtsma.png https://her2-2026.pp3.medonline.nl/wp-content/uploads/2024/11/Danny-Houtsma.png https://her2-2026.pp3.medonline.nl/positief-ciebom-advies-voor-enhertu-in-2l-her2-mbc/ 2024-12-20T16:09:56+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2022/12/Adviezen-commissie-CieBOM.png https://her2-2026.pp3.medonline.nl/bloedhersenbarriere-niet-langer-drempel-voor-behandeling/ 2024-12-20T16:10:24+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2022/12/Bloedhersenbarriere-niet-langer-drempel-voor-behandeling.png https://her2-2026.pp3.medonline.nl/nieuwe-evidence-based-esmo-therapierichtlijn-voor-gevorderd-mammacarcinoom-gepubliceerd/ 2024-12-20T16:12:50+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2021/10/ESMO-richtlijn.png https://her2-2026.pp3.medonline.nl/geen-twijfel-aan-meerwaarde-trastuzumab-deruxtecan-in-tweede-lijn-her2-mbc/ 2024-12-20T16:13:57+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2022/12/Inge-Konings-v2.png https://her2-2026.pp3.medonline.nl/enhertu-implementatie/ 2025-02-20T13:02:36+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2023/12/VS-Advertorial-e1711640543630.png https://her2-2026.pp3.medonline.nl/brochure-voor-zorgverleners/ 2025-02-20T13:07:11+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2022/01/HER2.png https://her2-2026.pp3.medonline.nl/verhindering-van-verwisselingen/ 2025-02-20T13:07:14+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2022/01/HER2.png https://her2-2026.pp3.medonline.nl/trastuzumab-deruxtecan-patientenkaart-voor-mogelijke-longproblemen/ 2025-02-20T13:07:22+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2022/01/HER2.png https://her2-2026.pp3.medonline.nl/bijwerkingen-t-dxd-over-het-algemeen-goed-te-managen/ 2025-02-20T13:07:35+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2023/10/HER@.png https://her2-2026.pp3.medonline.nl/enhertu-uit-de-sluis-vergoeding-voor-patienten-met-her2-mbc/ 2025-03-27T08:21:31+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2023/12/Staatscourant_vierkant.png https://her2-2026.pp3.medonline.nl/apotheker-brochure-enhertu-2/ 2025-06-05T08:57:38+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2024/01/HER2-nieuw.png https://her2-2026.pp3.medonline.nl/enhertu-brochure-behandeling-van-bijwerkingen/ 2025-06-05T09:14:00+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2024/01/HER2-nieuw.png https://her2-2026.pp3.medonline.nl/together2/ 2025-11-06T08:35:47+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2025/03/Marleen-Kok.png https://her2-2026.pp3.medonline.nl/wp-content/uploads/2025/10/Logo_Together2600.png https://her2-2026.pp3.medonline.nl/hersenmetastasen-bij-borstkanker/ 2025-11-06T08:35:58+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2025/04/Hersenmetas.jpg https://her2-2026.pp3.medonline.nl/informatiemateriaal-voor-uw-enhertu-patienten/ 2025-11-06T08:37:57+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2025/10/ENHU2535-Patientbrochure-en-Scheurblok-Enhertu-icoon-scaled.jpg https://her2-2026.pp3.medonline.nl/wp-content/uploads/2025/09/ENHU2535-Patientbrochure-Enhertu-icoon-kopie.jpg https://her2-2026.pp3.medonline.nl/wp-content/uploads/2025/09/ENHU2535-Scheurblok-Enhertu-icoon-kopie-2.jpg https://her2-2026.pp3.medonline.nl/wp-content/uploads/2025/09/Brochures_7talenV2.jpg https://her2-2026.pp3.medonline.nl/wp-content/uploads/2025/09/Patientvideo-ILD-.png https://her2-2026.pp3.medonline.nl/wp-content/uploads/2025/09/ILD.png https://her2-2026.pp3.medonline.nl/langetermijnresultaten-destiny-breast03-studie-bevestigen-betere-werkzaamheid-t-dxd-versus-t-dm1-bij-gemetastaseerd-her2-positief-mammacarcinoom/ 2025-11-06T08:40:43+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2024/07/dr-Kok.png https://her2-2026.pp3.medonline.nl/wp-content/uploads/2024/08/Foto_Marleen-Kok--scaled.jpg https://her2-2026.pp3.medonline.nl/substantieel-deel-van-de-patienten-met-her2-mbc-komt-niet-toe-aan-een-volgende-behandellijn/ 2025-11-06T08:42:00+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2024/09/Paul-Henri-Cottu.png https://her2-2026.pp3.medonline.nl/nieuwe-data-read/ 2025-11-06T08:44:27+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2024/06/Leontine-Spierings.png https://her2-2026.pp3.medonline.nl/experts-over-de-data-van-enhertu-bij-her2-mbc-met-en-zonder-hersenmetastasen/ 2025-11-06T08:48:46+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2024/11/Yara_baas.png https://her2-2026.pp3.medonline.nl/db-presentaties-en-publicaties/ 2025-11-28T09:31:28+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2024/01/Trastuzumab-Deruxtecan-DESTINY-Breast03-plaatje.png https://her2-2026.pp3.medonline.nl/wat-is-enhertu/ 2025-12-09T10:01:34+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2021/08/Schermafbeelding-2021-08-26-om-16.11.23-e1641915019823.png https://her2-2026.pp3.medonline.nl/enhertu-in-de-klinische-praktijk/ 2025-12-09T10:03:31+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2021/08/Schermafbeelding-2021-08-26-om-16.11.23-e1641915019823.png https://her2-2026.pp3.medonline.nl/wp-content/uploads/2024/11/Trastuzumab-deruxtecan-op-HER2-gericht-antilichaam-geneesmiddel-conjugaat-1.png https://her2-2026.pp3.medonline.nl/enhertu-implementatie-in-uw-ziekenhuis/ 2026-02-23T09:33:36+00:00 https://her2-2026.pp3.medonline.nl/wp-content/uploads/2023/12/Wheel-of-access.png